# A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

> **NCT07735546** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Umoja Biopharma** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma (MM)

## Interventions

- **GENETIC:** UB-VV500
- **DRUG:** Rapamycin (sirolimus)

## Key facts

- **NCT ID:** NCT07735546
- **Lead sponsor:** Umoja Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735546, "A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*